Alexion Pharmaceuticals (ALXN)
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Alexion Pharmaceuticals today and set a price target of $131.00. The company’s shares closed last Monday at $113.09.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 11.5% and a 61.4% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Vertex Pharmaceuticals, and Sarepta Therapeutics.
Alexion Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $148.91.
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on Neurocrine, with a price target of $121.00. The company’s shares closed last Monday at $105.77.
According to TipRanks.com, Hung is a 5-star analyst with an average return of 27.7% and a 70.3% success rate. Hung covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Voyager Therapeutics, and Prevail Therapeutics.
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $123.27, representing a 16.2% upside. In a report issued on January 10, Robert W. Baird also maintained a Buy rating on the stock with a $128.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.